肝细胞癌微血管侵犯的预测及治疗进展
何涛， 蒋禹， 李秋， 付文广 - 临床肝胆病杂志, 2020 - lcgdbzz.org
尽管目前肝细胞癌(HCC) 采用联合多学科, 多种方式的综合治疗, 但仍有很大部分患者预后较差.
现有研究表明微血管侵犯(MVI) 是HCC 发生不良预后的重要因素之一, 但目前MVI …
现有研究表明微血管侵犯(MVI) 是HCC 发生不良预后的重要因素之一, 但目前MVI …
18F-FDG PET/CT 纳入肝细胞癌肝移植标准的趋势与价值
蒲朝煜， 王剑杰， 周里， 陈虹 - 临床肝胆病杂志, 2020 - lcgdbzz.org
肝移植是治疗肝细胞癌(HCC) 的有效方法, 为降低HCC 肝移植术后可能出现较高肿瘤复发率,
有学者率先提出著名的Milan 标准. 但该标准过于严格, 部分患者因其肿瘤病变较大或多个结节 …
有学者率先提出著名的Milan 标准. 但该标准过于严格, 部分患者因其肿瘤病变较大或多个结节 …
Research advances in microvascular invasion in hepatocellular carcinoma
H Tao, J Yu, L Qiu, F WenGuang - 临床肝胆病杂志, 2020 - lcgdbzz.org
Although hepatocellular carcinoma (HCC) is treated with a combination of multiple
disciplines and methods, there are still a large number of patients with poor prognosis …
disciplines and methods, there are still a large number of patients with poor prognosis …
The trend and value of18F-FDG PET/CT included in the criteria for liver transplantation in hepatocellular carcinoma
P ChaoYu, W JianJie, Z Li, C Hong - 临床肝胆病杂志, 2020 - lcgdbzz.org
Liver transplantation is an effective method for the treatment of hepatocellular carcinoma
(HCC). In order to reduce the high recurrence rate of tumor after liver transplantation for …
(HCC). In order to reduce the high recurrence rate of tumor after liver transplantation for …